Psychedelics

Origins of Ethnopharmacology

Aspirin, Digoxin, and Morphine aren’t the first thing that comes to our minds once we hear the word Plant Medicine. Regardless of their seemingly distant origin, all those compounds once had a plant origin. To this, we name ethnopharmacology. Using the word of Juerg Gertsch: “Ethnopharmacology tries to understand the pharmacological basis of culturally important plants.”

Today, ethnopharmacology has an equally important role, as we are using plants that have been used for centuries by natives. Plants such as Peyote, Ayahuasca, Iboga, Kava Kava, and Psilocybe aid us with the current mental illness epidemic. Thus, Indigenous communities are once again furnishing us and aiding us with their ancient knowledge, this being said it would only be unfair not to feature such communities in Psychedelic and Ethnobotanical conferences, giving them their due credit, and teaching us about how much these plants mean to their culture, and most importantly how we should respect and protect indigenous rights.

Origins of Ethnopharmacology Read More »

The new religion of Psilomethoxin

The new internet-breaking tryptamine Psilomethoxin has generated various discussions on threads. Following breadcrumbs left by Alexander Shulgin, the owners of the Psilomethoxin church claimed to have successfully made the compound and report several experiences using it.

However, the discussion continues, from being a 4-hydroxylated orally active form of 5-MeO-DMT to a potential neurotoxin for its similarities to 4,5-dihydroxytryptamine it’s yet incognito whether the compound could have any neurotoxicity.

The new religion of Psilomethoxin Read More »

Psilocybin In the brain

Since the introduction of the Psilocybe genus to the western community, various genetic engineering experiences were made birthing various strains, among them the WillSolvem Peyote Strain.

Recent revolutionary research conducted by the Usona Institute unveiled for the first time the true crystal structure of psilocybin opening doors for new psilocybin analogs, such as CYB003, believed to hold the potential to treat major depressive disorder (MDD) and alcohol disorder. This analog is designed to have less variability in the plasma levels, a faster onset of action, shorter duration, and potentially be more tolerable versus oral psilocybin.

Along with the mycological and chemical discoveries, how the substance acts in the brain and its potential use for the treatment of clinical depression is also being explored together with the hypothesis of psilocybe altering the gut microbiome, thus creating a potential avenue for new pharmaceutical tools targeting the gut-brain axis.

Psilocybin In the brain Read More »

Shopping Cart